Wegovy

News

Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

News

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.

News

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Novo Nordisk has been criticised by the FDA for a TV ad for the Wegovy pill, which the agency claims makes "false and misleading" claims.

News

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.